TrialJournal of diabetes investigation2019

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.

Mitsuko Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.